May 13, 2025
Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions.
April 25, 2025
February 20, 2025
All stories
May 13, 2025
Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions.
April 25, 2025
Eleva confirms dry AMD as second indication for proprietary Factor H (CPV-104) program
February 20, 2025
Martin Bauer joins Eleva with over two decades of clinical development expertise, having held various management positions of increasing responsibility.
February 4, 2025
Eleva and 3PBIOVIAN sign strategic GMP manufacturing and technology alliance to boost capacity for Eleva’s platform and pipeline
Sep 19, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Jul 30, 2024
The CDMO landscape is evolving constantly. Our CSO and Managing Director Andreas Schaaf recently joined an insightful online webinar.
Jul 16, 2024
Eleva's bryotechnology revolutionizes biologics manufacturing. Björn talks about the critical roles of perseverance and innovation in the biotech industry.
July 3, 2024
Orphan Drug Designation for proprietary Factor H therapy in C3G adds significant value to the Factor H (CPV-104) program.
May 13, 2024
Data demonstrates the therapeutic potential of Factor H (CPV-104) as complement modulator and delivered preclinical proof-of-concept in C3G.
Jan 4, 2024
His appointment reflects the growing maturity of Eleva’s proprietary pipeline programs.
May 3, 2023
Serial entrepreneur and molecular biologist to lead Eleva into next development phase
Back to
